The hematological changes in COVID-19 patients; its relations to outcome in a retrospective study in Makkah city

Mohammed Aldosari1, Amal Zaghloul2,3, Hamid Mawlawi1, Talat Al-Bukhari3, Helalah Reda1, Muneera Albuloshi1, Yasser Hammadallah1, Amin Alharbi1, Yonis Alohibi3, Fozyah Alzahrani1, Asim A Khogeer4, Hend Al-Kulaity5, Hani Beheiry5.

1Department of Clinical Pathology, King Abdulaziz Hospital, Ministry of Health, Makkah, Saudi Arabia.
2Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
3Hematology and Immunology Department, Faculty of Medicine, Umm Al Qura University, Saudi Arabia.
4Plan and research department, ministry of Health, Makkah region, Saudi Arabia.
5Internal medicine Department, King Abdulaziz Hospital, Ministry of Health, Makkah, Saudi Arabia.

ABSTRACT

Purpose: To detect the frequency of hematological changes in Covid-19 patients at king Abdul Aziz hospital, Makkah, Saudi Arabia; to compare the outcome of patients with or without hematological changes.

Methods: This retrospective study included 537 patients. They were 0.6% asymptomatic, 22.9% mild to moderate, 31.1% severe, and 45.4% critical. According to the hematological results, patients were divided into normal, high, and low groups.

Results: Anemia was found in 50.9%, 26%, 21.4%, and 1.7% of critical, mild to moderate, severe, and asymptomatic cases, respectively. Polycythemia was detected in 16.7% and 83.3% of mild to moderate and critical cases, respectively. Thrombocytopenia was found in 44.4%, 30%, 25.6% of critical, mild to moderate and severe cases, respectively. Neutropenia was found in 40.9%, 36.4%, and 22.7% of critical, mild to moderate and severe cases. Neutrophilia was found in 58.2%, 24.1%, and 17.7% of critical, severe, and mild to moderate cases. Lymphopenia was found in 51%, 29.3%, 19.4%, and .3% of critical, severe, mild to moderate and asymptomatic patients. Monocytopenia was found in 55%, 30%, and 15% of critical, severe, and mild to moderate cases, respectively. Monocytosis was found in 59.3%, 25.4%, and 15.3% of critical, mild to moderate, and severe cases. The risk of death was 15.2, 2.4, 2.6, 1.9, 2.9, 2.1, 2.1 times higher in those with polycythemia, neutrophilia, monocytosis, lymphopenia, monocytopenia, diabetes, and age over 65, respectively.

Conclusion: Neutrophilia, monocytosis, lymphopenia, monocytopenia, and polycythemia, diabetic patients, and age over 65 are independent predictors for death.

Keyword: Covid-19, Neutrophilia, lymphopenia, monocytopenia, Makkah city.

Introduction

Coronavirus is a zoonotic RNA virus that can spread between animals and humans. Seven coronaviruses can infect humans, 4 of which are common pathogens of human colds, which do not cause serious illness. The remaining three coronaviruses are the severe acute respiratory syndrome coronavirus, the Middle East respiratory syndrome coronavirus, and the novel Coronavirus (SARS-COV-2), also known as COVID-19, cause severe disease to the human being. The COVID-19 was broke out in Wuhan, China, in December 2019 [1]. Then, it spreads worldwide, with 136 million confirmed cases and 2.94 million deaths [2]. The main manifestations of COVID-19 are fever,
Dry cough, and fatigue. Severely affected patients have dyspnea and hypoxemia one week after the onset of symptoms. They may develop acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation dysfunction, and multiple organ failure [3-5]. COVID-19 primarily affects the tissues expressing high ACE2 receptors (angiotensin-converting enzyme 2), including the lungs, heart, gastrointestinal tract, lymphocytes, kidney, and adipose tissue [6]. COVID-19 has effects on the hematopoietic system. Leukopenia, lymphopenia, neutrophilia, and thrombocytopenia are found in COVID-19 patients. They were more prominent among severe cases. The lymphopenia was related to the severity of COVID-19 patients. It could use to predict the severity and prognosis of patients [7-8]. In Saudi Arabia, the coronavirus cases were 399,277, of which 6,765 (1.7%) were dead, and 384,027 were recovered cases [9]. This study aimed to detect the frequency of hematological changes in COVID-19 patients and determine its relation to the severity and outcome of the disease.

Methods
A retrospective cohort study was conducted from November 2020 to August 2021 at King Abdul Aziz Hospital, Makkah, Saudi Arabia. The institutional review board (IRB) of Makkah research approved the protocol of this study, and the approval number was H-02-K-016-0820-331. We collected the data from the laboratory and medical records of King Abdul Aziz Hospital from September 2020 to December 2020. This study includes 537 hospitalized COVID-19 patients. They were classified clinically into asymptomatic 3 (0.6%), mild to moderate 123 (22.9%), severe 167 (31.3%), and critical 244 (45.4%). We have done a longitudinal follow-up of patients at admission, one week after admission, and at discharge (either living or death). The patients were divided into three groups according to the hematological values (normal, high, and low). Inclusion criteria: both genders, any age, positive COVID-19 by PCR. Exclusion criteria: Patients with negative COVID-19.

All the following data were collected from the patients:
1- Demographic and clinical data include age, sex, nationality, weight, height, body mass index, and history of hypertension or diabetes.
2- Complete blood count (CBC). The CBC was measured on Sysmex XT-2000 (Siemens diagnostic Germany).
3- Biochemical markers were measured on Architect c4000 clinical chemistry analyzer Abbott core laboratory.
4- The C reactive protein (CRP) and ferritin. The ferritin and CRP were measured by Cobas Integra 6000 analyzers and crescent diagnostics kit, K.S.A respectively.
5- Duration of staying at the hospital from admission to discharge.
6- Status of the patients at discharge, either living or death.

Statistical analysis
The statistical analysis of this study used the SPSS program version 20. The comparison between groups for the quantitative data was performed using the Student t-test, the Mann–Whitney U test, and Friedman test according to the data distribution, the number of groups, and dependent or independent sample. The chi-square test, or the Fisher exact test, and the relative risk ratio of death were used for the qualitative data. The Bivariate logistic regression model was conducted to determine the independent predictor factors for death. A two-sided p-value ≤0.05 was considered to represent a statistically significant difference.

Results
The results of this study were summarized from table 1 to 8. The demographic and clinical data of the patients were summarized in (Table 1). The frequency of the hematological changes at admission (Table 2). The patients were divided into groups normal, high, and low according to the variations of the hematological parameters. 63.8% had normal white blood cell count (WBC), 30.2% had high, and 6% had low count. 71.4% of males had normal hemoglobin, 1.3% had high, and 27.2% had low hemoglobin. 55.3% of females had normal hemoglobin, 0.6% had high, and 44% had low hemoglobin. The platelet count was normal in 75.6% of patients, increased in 7.6%, and low in 16.8%. The absolute neutrophil count (ANC) was normal in 48.9% of patients, elevated in 46.4% and low in 4.6%. The absolute lymphocyte count (ALC) was normal in 37% of patients, elevated in 0.8% and low in 62.2%. The absolute monocyte count (AMC) was normal in 83.3%, high in 12.5%, and low in 4.2%. The absolute eosinophil count (AEC) was normal in 99.2% and high in 0.8%. The absolute basophil count (ABC) was normal in 89.2% and high in 10.8%. The associations between hematological parameters and severity of disease at admission (Table 3). The frequency of normal WBC was 24.8%, 35%, 39.4%, and 0.9% in mild to moderate, severe, critical, and asymptomatic cases. The frequency of leukocytosis was 16%, 22.2%, 61.7%, and 0% in mild to moderate, severe, critical, and asymptomatic, respectively. The frequency of leukopenia was 37.5%, 34.3%, 28.1%, and 0% in mild to moderate, severe, critical, and asymptomatic. The frequency of normal hemoglobin was 21.5%, 36.3%, 42.2%, and 0% in mild to moderate, severe, critical, and asymptomatic. The frequency of polycythemia was 16.7%, 0%,
83.3%, and 0% in mild to moderate, severe, critical, and asymptomatic, respectively. The frequency of anemia was 26%, 21.4%, 50.9%, and 1.7% in mild to moderate, severe, critical, and asymptomatic, respectively. The frequency of normal platelets was 21.2%, 32%, 46.3%, and 0.5% in mild to moderate, severe, critical, and asymptomatic. The frequency of thrombocytosis was 24.4%, 34.1%, 39%, and 2.4% in mild to moderate, severe, critical, and asymptomatic, respectively. The frequency of thrombocytopenia was 30%, 25.6%, 44.4%, and 0% in mild to moderate, severe, critical, and asymptomatic, respectively. The frequency of normal ANC was 25%, 36.2%, 37.5%, and 1.3% in mild to moderate, severe, critical, and asymptomatic. The neutrophilia frequency was 17.7%, 24.1%, and 58.2% in mild to moderate, severe, and critical. In mild to moderate, severe, and critical cases, the frequency of neutropenia was 36.4%, 22.7%, and 40.9%. The frequency of normal lymphocyte count was 25.3%, 31%, 43.1%, and 0.6% in mild to moderate, severe, critical, and asymptomatic. The frequency of lymphocytosis was 100% in mild to moderate cases. The frequency of lymphopenia was 19.4%, 29.3%, 51%, and 0.3% in mild to moderate, severe, critical, and asymptomatic. The frequency of normal monocyte count was 22.3%, 31.5%, 45.4%, and 0.8% in mild to moderate, severe, critical, and asymptomatic. The frequency of monocytes was 25.4%, 15.3%, and 59.3% in mild to moderate, severe, and critical. The frequency of normal eosinophil count was 21.7%, 29.9%, 48%, and 0.4% in mild to moderate, severe, critical, and asymptomatic. The frequency of eosinophilia was 50%, 0%, 25%, and 25% in mild to moderate, severe, critical, and asymptomatic. The frequency of normal basophil count was 21.6%, 30.6%, 47.2%, and 0.7% in mild to moderate, severe, critical, and asymptomatic. The frequency of basophilia was 25.5%, 21.6%, and 52.9% in mild to moderate, severe, and critical. The frequency of combined leukocytosis, neutrophilia, and lymphopenia was present in 14.3%, 20.9%, and 65.7% in mild to moderate, severe, and critical. The frequency of combined leukocytosis, neutrophilia, lymphopenia, and thrombocytopenia was present in 14.3% and 85.7% of severe and critical cases. The outcome of patients (Table 4-5): Out of 537 hospitalized patients, 67% were survivors, and 33% were non-survivor. The fatality rate of death was 0.8%, 0.6%, 71.7%, and 0% in mild to moderate, severe, critical, and asymptomatic cases, respectively. The percentage of death was 23.8%, 33.6% and 43.2% for those < 40 years, >40≤ 65 y and > 65 respectively p<0.05. 30.4% of males were dead versus 39% of females, with no significant difference p>0.05. 43.5% of hypertensive patients have died versus 28.7% without hypertension p<0.05. 43.1% of diabetic patients have died versus 27.5% without diabetes mellitus p<0.05. 43.3% of obese patients died versus 30.9% non-obese p<0.05. For those with normal, high, and low white blood cell count, the percentage of death was 26%, 50%, and 25%, respectively, with a significant difference between the high and normal group p<0.05. For males with normal, high, and low hemoglobin concentration, the percentage of death was 27.8%, 80%, and 35%, respectively, with a significant difference between the high and normal group p<0.05. For females with normal, high, and low hemoglobin concentration, the percentage of death was 35.2%, 100%, and 42.9%, respectively, with no significant difference. For those with normal, high, and low platelets count, the percentage of death was 32.3%, 31.7%, and 36.7%, respectively, with no significant difference. For those with a normal, high, and low absolute neutrophil count, the percentage of death was 24.6%, 45.0%, and 27.3%, respectively, with a significant difference between the high and normal groups. For those with normal, high, and low absolute lymphocytes count, the percentage of death was 28.2%, 20%, 38.8%, with a significant difference between normal and low. For those with normal, high, and low absolute monocyte count, the percentage of death was 32.1%, 52.5%, and 55%, with a significant difference between normal and each of low and high p<0.05. For those with normal and high absolute eosinophils and basophil count, the percentage of death was 34.8%, versus 25% and 34.1% versus 41.2%, respectively, with no significant difference p>0.05. For those with leukocytosis, neutrophilia, lymphopenia, the percentage of death was 55.2% versus 29.8% for those without this combination. For those with leukocytosis, neutrophilia, lymphopenia, and thrombocytopenia, the death rate was 85.7% versus 32.3% for those without this combination. There was a significant difference in both combinations. The relative risk of death using demographic, clinical data, and patient hematological parameters (Tables 4-5). The relative risk (RR) of death was significantly higher in those with hypertension, diabetes, combined hypertension, and diabetes, aged > 40 years, and obese patients when compared to those without disease and aged < 40 years p<0.05. The RR of death was 1.5, 1.6, 1.5, 0.7, and 0.7, respectively. The RR of death was 105 times in the critical group versus the combination of other groups, (Table 4). The RR of death showed a significant increase in those with leukocytosis, polycythemia, neutrophilia, lymphopenia, monocytes, and monocytopenia compared to those with normal values p<0.05. The RR of death was 0.5, 0.3, 0.5, 0.7, 0.6 and 0.6 respectively. The relative risk of death significantly increased in those with combined leukocytosis, neutrophilia, lymphopenia or
combined leukocytosis, neutrophilia, lymphopenia, and thrombocytopenia when compared to those without these changes. The RR of death was 1.9 and 2.7 respectively, p<.05, (Table 5). Follow up of patients using the hematological parameters in survivors and non-survivors patients (Table6): In the survivor patients, the normal group showed a significant increase in WBC, ANC, ALC, AMC, AEC, ABC, and platelet count. Also, there was a significant decrease in hemoglobin. A significant decrease of WBC, AMC, ABC, and platelets was found in the high group. In addition, the low group showed a significant increase in WBC, ALC, AMC, and platelet count. In the non-survivor patients, there was a significant increase in WBC, ANC, and ABC in the normal group. In addition, there was a significant decrease in ALC and platelet count. In the high group, there was a significant decrease in AMC, ABC, and platelets count. The low group showed a significant increase in WBC count, a significant reduction in ALC and platelet count. There was a significant decrease in hemoglobin in the three groups. Comparison between survivors and non-survivors regarding hematological, biochemical markers, demographic data, and the number of days stayed at hospital (Table 7). At presentation, there were significant increases in age, body mass index, WBC, ANC, ABC, serum creatinine, LDH, SGOT, and CRP in non-survivor patients compared to the survivor, p<0.05. At discharge, there was a significant increase in WBC, ANC, serum creatinine, LDH, SGOT, SGPT, CRP, ferritin, and the number of days stayed at the hospital. There was a significant decrease in hemoglobin concentration, platelet count, ALC, and AEC in the non-survivor versus the survivor. The effects of hematological and clinical data on the likelihood that patients with COVID-19 will die using the bivariate logistic regression model. (Table 8). The odd of death was 2.4, 2.6, and 1.9. 2.9 times greater for patients with neutrophilia, monocyctosis, lymphopenia, and monocyctopenia than those with normal values. The odd of death were 15.2 times greater for patients with high hemoglobin versus those with normal hemoglobin. The odd of death were 2.1 times greater for patients above 65 years of age than those under 40 years. The odd of death was 2.1 times greater for diabetic patients than non-diabetic.

**Discussion**

The COVID-19 virus infection has an impact on the hematopoietic system. This study aimed to determine the frequency of hematological changes in COVID-19 and their relationship to patients’ severity and outcome. In this work, 30.2%, 46.5%, 1%, 12.5%, 0.8%, and 10.8% had leukocytosis, neutrophilia, lymphocytosis, monocyctosis, eosinophilia and basophilia respectively at admission. The white blood cells (WBC) are part of the immune system, and both the neutrophils and monocytes are the main phagocytic cells. The elevation of the WBC and its differential count in a percentage of patients at admission may be due to the increased production and mobilization of WBC from the bone marrow in response to acute infections. Or inhibition of margination [10] or hypoxia. Hypoxia inhibits neutrophil apoptosis and subsequently increases neutrophil numbers [11]. In this work, 61.7%, 58.2%, 59.3%,52.9% of leukocytosis, neutrophilia, monocyctosis, eosinophilia, and basophilia were present in the critical cases at presentation. The remaining percentages were distributed in mild to moderate and severe cases. In COVID-19 patients, it is known that neutrophilia predicts poor outcomes [12]. Our work confirmed this by the significant elevation of WBC and absolute neutrophil count (ANC) at admission and at discharge in the non-survivor patients compared to the survivor, table 7. In addition, a significant increase in WBC and ANC in the normal group of the non-survivor patients during the follow-up. Also, the sustained elevation of WBC and ANC in the high group of the non-survivor patients during the follow-up procedure. Moreover, the relative risk of death was significantly increased in patients with leukocytosis and neutrophilia compared to those without. Also, in bivariate regression analysis, neutrophilia was an independent predictor of death. All these results confirm the assumption that neutrophilia is a poor prognostic factor. The neutrophilia may be due to the cytokine storm or the hypoxia present in the patients [11]. In this work, 12.5% at presentation had absolute monocyctosis, 59.3% were present in critical cases. This agrees with previous authors [13]. The monocytes are increased because they are part of the innate immune system [14] that participate in inflammatory responses. Also, monocytes are key contributors to cytokine storm in COVID-19 [15] via the production of IL-6. IL-6 leads to fever, granulopoiesis, hematopoiesis, and the accumulation of neutrophils at sites of infection. Our work confirmed this by the significant positive correlation between the AMC and the ANC (p<.001, r.525 data not shown). In this work, the relative risk of death was significantly increased in those with monocyctosis versus the normal group. Also, in bivariate regression analysis, monocyctosis had a 2.6 times risk of death than those with normal monocytes count. So, monocyctosis could be used as a poor prognostic factor and independent predictor for death. In the follow-up of patients with monocyctosis in the non-survivor and survivor patients. There was a significant decrease in the absolute monocytes count, which indicates a reduction in the former's immune function and recovery in the latter.
The hematological changes in COVID-19 patients; its relations to outcome in a retrospective study in Makkah city

Table 1: Demographic and clinical data of the participants.

|                |  
|----------------|--------------------------------------------------|
|                | **no=537** | **%** |
| **Age**        |            |       |
| Mean ±SD       | 52.2 ± 15.7 | 52.00 |
| Min-max        | 14-93      |       |
| **Sex**        |            |       |
| Male           | 378        | 70.4  |
| Female         | 159        | 29.6  |
| **Nationality**|            |       |
| Afghan         | 8          | 1.5   |
| Ethiopian      | 2          | 0.4   |
| Bangladeshi    | 48         | 8.9   |
| Burkinabe      | 1          | 0.2   |
| Chinese        | 3          | 0.6   |
| Egyptian       | 27         | 5.0   |
| Indian         | 20         | 3.7   |
| Indonesian     | 14         | 2.6   |
| Iraqi          | 1          | 0.2   |
| Jordanian      | 1          | 0.2   |
| Malian         | 7          | 1.3   |
| Malaysian      | 1          | 0.2   |
| Myanmar        | 60         | 11.2  |
| Mauritanian    | 2          | 0.4   |
| Moroccan       | 1          | 0.2   |
| Nigerian       | 20         | 3.7   |
| Pakistani      | 53         | 9.9   |
| Palestinian    | 3          | 0.6   |
| Filipino       | 1          | 0.2   |
| Saudi          | 165        | 30.7  |
| Sudanese       | 12         | 2.2   |
| Syrian         | 12         | 2.2   |
| Thai           | 4          | 0.7   |
| Turkish        | 3          | 0.6   |
| Yemeni         | 56         | 10.4  |
| **BMI**        |            |       |
| Normal         | 288        | 53.6  |
| Overweight     | 157        | 29.2  |
| Obese          | 90         | 16.8  |
| Underweight    | 2          | 0.4   |
| **Hypertension**|       |       |
| Yes            | 154        | 28.7  |
| No             | 383        | 71.3  |
| **Diabetes**   |            |       |
| Yes            | 188        | 35    |
| No             | 349        | 65    |
| **DM&HTN**     |            |       |
| Yes            | 102        | 19    |
| No             | 435        | 81    |
| **Severity of disease** |  |       |
| Asymptomatic   | 3          | 0.6   |
| Mild to moderate | 123     | 22.9  |
| Severe         | 167        | 31.1  |
| Critical       | 244        | 45.4  |

*DM= diabetes mellites, HTN= hypertension
The hematological changes in COVID-19 patients; its relations to outcome in a retrospective study in Makkah city

Table 2: The frequency of hematological changes in COVID-19 patients at admission.

| Parameters     | Frequency | Percent | Parameters     | Frequency | Percent |
|----------------|-----------|---------|----------------|-----------|---------|
| WBC \((n=537)\) |           |         | ANC \((n=474)\) |           |         |
| Normal         | 343       | 63.8    | Normal         | 232       | 48.9    |
| High           | 162       | 30.2    | High           | 220       | 46.4    |
| Low            | 32        | 6.0     | Low            | 22        | 4.6     |
| Hemoglobin\(^1\) \((n=378)\) |       |         | ALC \((n=473)\) |           |         |
| Normal         | 270       | 71.4    | Normal         | 175       | 37      |
| High           | 5         | 1.3     | High           | 4         | .8      |
| Low            | 103       | 27.2    | Low            | 294       | 62.2    |
| Hemoglobin\(^2\) \((n=159)\) |       |         | AMC \((n=473)\) |           |         |
| Normal         | 88        | 55.3    | Normal         | 394       | 83.3    |
| High           | 1         | .6      | High           | 59        | 12.5    |
| Low            | 70        | 44      | Low            | 20        | 4.2     |
| Platelets \((n=537)\) |       |         | AEC \((n=473)\) |           |         |
| Normal         | 406       | 75.6    | Normal         | 469       | 99.2    |
| High           | 41        | 7.6     | High           | 4         | 0.8     |
| Low            | 90        | 16.8    | ABC \((n=473)\) |           |         |
|                |           |         | Normal         | 422       | 89.2    |
|                |           |         | High           | 51        | 10.8    |

WBC= white blood cells; ANC=absolute neutrophil count; ALC= absolute lymphocyte count; AMC= absolute monocyte count; AEC= absolute eosinophil count; ABC=absolute basophil count. Hemoglobin 1= male; hemoglobin 2= female
The hematological changes in COVID-19 patients; its relations to outcome in a retrospective study in Makkah city

Table 3: The associations between hematological parameters and severity of the disease at admission.

|                  | Mild to moderate (n=123) | Severe (n=167) | Critical (n=244) | Asymptomatic (N=3) | Total no. | P-value |
|------------------|--------------------------|----------------|------------------|--------------------|-----------|---------|
|                  | no | %  | no | %  | no | %  | no | %  | no | %  |
| **WBC**          |    |     |    |     |    |     |    |     |    |     |
| Normal           | 85 | 24.8 | 120 | 35  | 135 | 39.4 | 3  | .9  | 343 | <.001|
| High             | 26 | 16  | 36 | 22.2 | 100 | 61.7 | 0  | 0   | 162 | .32  |
| Low              | 12 | 37.5 | 11 | 34.4 | 9  | 28.1 | 0  | 0   | 32  |       |
| **Hb**           |    |     |    |     |    |     |    |     |    |     |
| Normal           | 77 | 21.5 | 130 | 36.3 | 151 | 42.2% | 0  | 0   | 358 | .001 |
| High             | 1  | 16.7 | 0  | 0   | 5  | 83.3 | 0  | 0   | 6   |       |
| Low              | 45 | 26  | 37 | 21.4 | 88 | 50.9 | 3  | 1.7 | 173 |       |
| **Platelets**    |    |     |    |     |    |     |    |     |    |     |
| Normal           | 86 | 21.2 | 130 | 32.0 | 188 | 46.3 | 2  | .5  | 406 | .298 |
| High             | 10 | 24.4 | 14 | 34.1 | 16 | 39  | 1  | 2.4 | 41  |       |
| Low              | 27 | 30  | 23 | 25.6 | 40 | 44.4 | 0  | 0   | 90  |       |
| **ANC**          |    |     |    |     |    |     |    |     |    |     |
| Normal           | 58 | 25  | 84 | 36.2 | 87 | 37.5 | 3  | 1.3 | 232 | <.001|
| High             | 39 | 17.7 | 53 | 24.1 | 129 | 58.2 | 0  | 0   | 220 |       |
| Low              | 8  | 36.4 | 5  | 22.7 | 9  | 40.9 | 0  | 0   | 22  |       |
| **ALC**          |    |     |    |     |    |     |    |     |    |     |
| Normal           | 44 | 25.3 | 54 | 31  | 75 | 43.1 | 1  | .6  | 174 | .038 |
| High             | 4  | 100 | 0  | 0   | 0  | 0   | 0  | 0   | 0   |       |
| Low              | 57 | 19.4 | 86 | 29.3 | 150 | 51  | 1  | .3  | 294 |       |
| **AMC**          |    |     |    |     |    |     |    |     |    |     |
| Normal           | 88 | 22.3 | 124 | 31.5 | 179 | 45.4 | 3  | .8  | 394 | .220 |
| High             | 15 | 25.4 | 9  | 15.3 | 35 | 59.3 | 0  | 0   | 59  |       |
| Low              | 3  | 15  | 6  | 30  | 11 | 55  | 0  | 0   | 20  |       |
| **AEC**          |    |     |    |     |    |     |    |     |    |     |
| Normal           | 102 | 21.7 | 140 | 29.9 | 225 | 48  | 2  | .4  | 469 | <.001|
| High             | 2  | 50  | 0  | 0   | 1  | 25  | 1  | 25  | 4   |       |
| **ABC**          |    |     |    |     |    |     |    |     |    |     |
| Normal           | 91 | 21.6 | 129 | 30.6 | 199 | 47.2 | 3  | .7  | 422 | .523 |
| High             | 13 | 25.5 | 11 | 21.6 | 27 | 52.9 | 0  | 0   | 51  |       |
| **WBC+ANC+ALC**  |    |     |    |     |    |     |    |     |    |     |
| Normal           | 9  | 13.4 | 14 | 20.9 | 44 | 65.7 | 0  | 0   | 67  | .018 |
| WBC+ANC+ALC+Platelets | 0  | 0  | 1 | 14.3 | 6  | 85.7 | 0  | 0   | 7   |       |
| WBC+ANC+Platelets | 1  | 33.3 | 0  | 0   | 2  | 66.7 | 0  | 0   | 3   |       |
| Others           | 113 | 24.6 | 152 | 33  | 192 | 41.7 | 3  | .7  | 460 |       |

WBC=leukocytosis, ANC=neutrophilia, ALC=lymphopenia, Platelets=thrombocytopenia
The hematological changes in COVID-19 patients; its relations to outcome in a retrospective study in Makkah city

Table 4: The relative risk of death using demographic and clinical data of patients using Chi-Square test.

|                           | Living no / (%) | Death no / (%) | Total no. | RRE of death | Significance |
|---------------------------|-----------------|----------------|-----------|--------------|--------------|
| **Age**                   |                 |                |           |              |              |
| <40 y (G1)                | 109 (76.2)      | 34 (23.8)      | 143       | .708<sup>a</sup> |              |
| >40≤ 65 (G2)              | 188 (66.4)      | 95 (33.6)      | 283       | .550<sup>b</sup> | .001<sup>b</sup> |
| > 65 (G3)                 | 63 (56.8)       | 48 (43.2)      | 111       | .776<sup>c</sup> | .072<sup>c</sup> |
| **Sex**                   |                 |                |           |              |              |
| Male                      | 263(69.6)       | 115(30.4)      | 378       | .780         | .054         |
| Female                    | 97 (61)         | 62 (39)        | 159       |              |              |
| **Hypertension**          |                 |                |           |              |              |
| Yes                       | 87 (56.5)       | 67 (43.5)      | 154       | 1.515        | .001         |
| No                        | 273 (71.3)      | 110 (28.7)     | 383       |              |              |
| **Diabetes**              |                 |                |           |              |              |
| Yes                       | 107(56.9)       | 81(43.1)       | 188       | 1.566        | <.001        |
| No                        | 253 (72.5)      | 96 (27.5)      | 349       |              |              |
| **DM&HTN**                |                 |                |           |              |              |
| Yes                       | 55 (53.9)       | 47 (46.1)      | 102       | 1.542        | .002         |
| No                        | 305 (70.1)      | 130 (29.9)     | 435       |              |              |
| **BMI**                   |                 |                |           |              |              |
| Non obese                 | 309(69.1)       | 138(30.9)      | 447       | .712         | .027         |
| Obese                     | 51(56.7)        | 39(43.3)       | 90        |              |              |
| **Severity of disease**   |                 |                |           |              |              |
| Asymptomatic              | 3(100)          | 0(0)           | 3(.6)     | *105.0       | <.001        |
| Mild to moderate          | 122(99.2)       | 1(0.8)         | 123(22.9) |              |              |
| Severe                    | 166 (99.4)      | 1(.6)          | 167(31.1) |              |              |
| Critical                  | 69(28.3)        | 175(71.7)      | 244(45.4) |              |              |

a G1 versus G2; b G1 versus G3; c G2 versus G3; DM= diabetes; HTN= hypertension.

*between critical group versus the combination of other groups
The hematological changes in COVID-19 patients; its relations to outcome in a retrospective study in Makkah city

Table 5: The relative risk of death using the hematological parameters.

|                         | Living no / (%) | Death no / (%) | Total no. | RR of death | P value |
|-------------------------|-----------------|----------------|-----------|-------------|---------|
| **WBC**                 |                 |                |           |             |         |
| Normal/high             | 255 (74.3)/81(50) | 88 (25.7)/81(50) | 343/162 | .521        | <.001   |
| Normal/low              | 255 (74.3)/24(75) | 88(25.7)/8(25)   | 343/32   | .868        | 1.026   |
| High/low                | 81 (50)/24(75)  | 81(50)/8(25)     | 162/32   | 2.0         | .010    |
| **Hemoglobin<sup>1</sup>** |                |                |           |             |         |
| Normal/high             | 195 (72.2)/1(20) | 75(27.8)/4(80)   | 270/5    | .347        | .025    |
| Normal/low              | 195 (72.2)/67(65) | 75(27.8)/36(35)  | 270/103  | .795        | .175    |
| High/low                | 1(20)/67(65)    | 4(80)/36(35)     | 5/103    | 2.289       | .062    |
| **Hemoglobin<sup>2</sup>** |                |                |           |             |         |
| Normal/high             | 57(64.8)/0(0)   | 31(35.2)/1(100)  | 88/1     | .352        | .360    |
| Normal/low              | 57(64.8)/40(57.1) | 31(35.2)/30(42.9) | 88/70    | .822        | .328    |
| High/low                | 0(0)/40(57.1)   | 1(100)/30(42.9)  | 1/70     | 2.333       | .437    |
| **Platelets**           |                 |                |           |             |         |
| Normal/high             | 275(67.7)/28(68.3) | 131(32.3)/13(31.7) | 406/41   | 1.018       | .942    |
| Normal/low              | 275(67.7)/57(63.3) | 131(32.3)/33(36.7) | 406/90   | .880        | .422    |
| High/low                | 28(68.3)/57(63.3) | 13(31.7)/33(36.7) | 41/90    | .865        | .581    |
| **ANC**                 |                 |                |           |             |         |
| Normal/high             | 175(75.4)/121(55) | 57(24.6)/99(45.0) | 232/221  | .546        | <.001   |
| Normal/low              | 175(75.4)/16(72.7) | 57(24.6)/6(27.3)  | 232/22   | .901        | .779    |
| High/low                | 121(55)/16(72.7) | 99(45.0)/6(27.3)  | 221/22   | 1.659       | .105    |
| **ALC**                 |                 |                |           |             |         |
| Normal/High             | 125(71.8)/4(80)  | 49(28.2)/1(20)   | 174/5    | 1.4         | .688    |
| Normal/Low              | 125(71.8)/180(61.2) | 49(28.2)/114(38.8) | 174/294  | .726        | .020    |
| High/Low                | 4(80)/180(61.2)  | 1(20)/114(38.8)  | 5/294    | .516        | .392    |
| **AMC**                 |                 |                |           |             |         |
| Normal/High             | 272(69.2)/28(47.5) | 122(32.1)/31(52.5) | 394/59   | .589        | .002    |
| Normal/low              | 272(69.2)/9(45)  | 122(32.1)/11(55)  | 394/20   | .563        | .025    |
| High/low                | 272(69.2)/28(47.5) | 31(52.5)/11(55)   | 59/20    | .955        | .849    |
| **AEC**                 |                 |                |           |             |         |
| Normal/High             | 306(65.2)/3(75)  | 163(34.8)/1(25)   | 469/4    | 1.4         | .683    |
| **ABC**                 |                 |                |           |             |         |
| Normal/High             | 278(65.9)/30(58.8) | 144(34.1)/21(41.2) | 422/51   | .829        | .318    |
| leukocytosis +neutrophilia +lymphopenia | 30 (44.8)/330 (70.2) | 37 (55.2)/140(29.8) | 67/460 | 1.9         | <.001   |
| Yes/No                  | 1 (14.3)/359(67.7) | 6 (85.7)/171(32.3) | 7/530    | 2.657       | .003    |

Hemoglobin<sup>1</sup> = male, Hemoglobin<sup>2</sup> = female, ANC= absolute neutrophil count, ALC= absolute lymphocyte count; AMC= absolute monocyte count; AEC= absolute eosinophil count.
The hematological changes in COVID-19 patients; its relations to outcome in a retrospective study in Makkah city

Table 6: Follow up of patients using the hematological parameters in survivors and non-survivors.

| Survivor       | Normal (median) | High (median) | Low (median) |
|----------------|----------------|---------------|--------------|
|                | No | 1st | 2nd | 3rd | P | No | 1st | 2nd | 3rd | P | No | 1st | 2nd | 3rd | P |
| WBC            |    |     |     |     |   |    |     |     |     |   |    |     |     |     |   |
| Survivor       | Normal (median) | High (median) | Low (median) |
|                | No | 1st | 2nd | 3rd | P | No | 1st | 2nd | 3rd | P | No | 1st | 2nd | 3rd | P |
| WBC            |    |     |     |     |   |    |     |     |     |   |    |     |     |     |   |
| ANC            | 51 | 4.4 | 6.4 | 8.1 | <.001 | 42 | 9.3 | 10.5 | 8.6 | .242 | 16 | .934 | 1.9 | 1.4 | .135 |
| ALC            | 39 | 1.8 | 1.4 | 1.9 | .015 | 3 | 6.7 | 3.2 | 3.2 | .148 | 59 | .94 | 1.04 | 1.22 | .002 |
| AMC            | 90 | .500 | .622 | .654 | .002 | 28 | 1.3 | 1.1 | .719 | .019 | 3 | .0930 | .150 | .173 | .050 |
| AEC            | 96 | .0040 | .0125 | .0305 | .038 | 1 | .420 | .290 | .840 | ----- | --- |
| ABC            | 91 | .0340 | .0560 | .0680 | <.001 | 30 | .145 | .0600 | .0790 | .044 |
| Platelets      | 233 | 237.6 | 295.6 | 314.0 | <.001 | 26 | 477.4 | 432.3 | 458.2 | .016 | 57 | 123.6 | 169.7 | 217.3 | <.001 |
| Hb male        | 187 | 145.8 | 140.1 | 136.4 | <.001 | 1 | 186.5 | 184.2 | 165.0 | ----- | --- |
| Hb female      | 51 | 130 | 126.0 | 129.8 | .02 | 0 | 0 | 0 | 0 | 0 | 37 | 107.0 | 101.0 | 100.0 | .865 |

Non-survivor

| WBC            | 87 | 7.0 | 13.4 | 14.6 | <.001 | 80 | 15 | 17.2 | 16.4 | .549 | 6 | 3.3 | 9.0 | 10.4 | .04 |
| ANC            | 35 | 5.0 | 12.7 | 12.66 | <.001 | 43 | 11.9 | 14.9 | 14.7 | .231 | 6 | 1.6 | 7.1 | 12.3 | .097 |
| ALC            | 25 | 2.0 | 1.2 | .91 | <.001 | 0 | 0 | 0 | 0 | 0 | 1.04 | .55 | .75 | .039 |
| AMC            | 65 | .444 | .493 | .568 | 1.0 | 31 | 1.37 | .665 | .381 | .013 | 4 | .0900 | .513 | .421 | .174 |
| AEC            | 81 | .0020 | .0070 | .0100 | .068 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ABC            | 69 | .0300 | .0580 | .0630 | <.001 | 21 | .145 | .0545 | .0535 | .001 |
| Platelets      | 131 | 238.7 | 263.7 | 190.8 | <.001 | 12 | 490.7 | 330.1 | 257.1 | .002 | 30 | 123 | 136.7 | 93.2 | .048 |
| Hb male        | 74 | 146.5 | 126.5 | 112.9 | <.001 | 4 | 184.3 | 146.7 | 105.9 | .039 | 36 | 114.9 | 100.2 | 96.0 | .003 |
| Hb female      | 31 | 130.6 | 105.7 | 90.0 | <.001 | 1 | 164.4 | 124.0 | 111.0 | ----- | --- |

---

Table 6: Follow up of patients using the hematological parameters in survivors and non-survivors.
The hematological changes in COVID-19 patients; its relations to outcome in a retrospective study in Makkah city

| Table 7: Comparison between survivors and non-survivors with regards to hematological parameters, biochemical markers, and days stayed in the hospital at presentation and discharge. |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
| WBC                            | Participants    | N               | Median at presentation | Median at discharge | P value     |
|                                | Survivors       | 360             | 7.7                  | 9                | P1<.001     |
|                                | Non-survivors   | 177             | 10.2                 | 14.9             | P2<.001     |
| Hemoglobin                     | Survivors       | 360             | 136.3                | 129.7            | P1.161      |
|                                | Non-survivors   | 177             | 132                  | 95.6             | P2<.001     |
| Platelets                      | Survivors       | 360             | 227.4                | 304.3            | P1.519      |
|                                | Non-survivors   | 177             | 226.5                | 174.6            | P2<.001     |
| Neutrophil*                    | Survivors       | 312             | 5.7                  | 7.2              | P1<.001     |
|                                | Non-survivors   | 164             | 8.6                  | 13.3             | P2<.001     |
| Lymphocytes*                   | Survivors       | 309             | 1.3                  | 1.5              | P1.133      |
|                                | Non-survivors   | 164             | 1.2                  | .773             | P2<.001     |
| Monocytes*                     | Survivors       | 310             | .48                  | .640             | P1.082      |
|                                | Non-survivors   | 164             | .52                  | .590             | P2=.278     |
| Eosinophils *                  | Survivors       | 309             | .0040                | .032             | P1.438      |
|                                | Non-survivors   | 164             | .0030                | .0100            | P2<.001     |
| Basophils*                     | Survivors       | 308             | .0300                | .0660            | P1.029      |
|                                | Non-survivors   | 164             | .0385                | .0630            | P2=.404     |
| Creatinine                     | Survivors       | 355             | 83.5                 | 70.5             | P1<.001     |
|                                | Non-survivors   | 176             | 105.8                | 162.4            | P2<.001     |
| LDH                            | Survivors       | 292             | 404                  | 319.5            | P1<.001     |
|                                | Non-survivors   | 161             | 470                  | 525              | P2<.001     |
| SGOT                           | Survivors       | 353             | 53                   | 38               | P1.029      |
|                                | Non-survivors   | 174             | 63.5                 | 65               | P2<.001     |
| SGPT                           | Survivors       | 355             | 39                   | 47               | P1.308      |
|                                | Non-survivors   | 176             | 35.5                 | 62               | P2=.002     |
| CRP                            | Survivors       | 232             | 48                   | 24               | P1.031      |
|                                | Non-survivors   | 132             | 48                   | 48               | P2=.022     |
| Ferritin                       | Survivors       | 244             | 593                  | 791.7            | P1.168      |
|                                | Non-survivors   | 134             | 739                  | 1318             | P2=.003     |
| Days in hospital               | Survivors       | 360             | ---------            | 10               | P2<.001     |
|                                | Non-survivors   | 177             | ---------            | 15               |             |
| Age                            | Survivors       | 360             | 50                   | ---------         | P1<.001     |
|                                | Non-survivors   | 177             | 58                   | ---------         |             |
| BMI                            | Survivors       | 360             | 24.6                 | ---------         | P1=.008     |
|                                | Non-survivors   | 177             | 25.4                 | ---------         |             |

p1= at presentation, p2= at discharge
The hematological changes in COVID-19 patients; its relations to outcome in a retrospective study in Makkah city

**Table 8:** Bivariate regression analysis of the hematological and clinical parameters.

|         | B    | Wald | Sig. | Exp(B) | Lower | Upper |
|---------|------|------|------|--------|-------|-------|
| Hb groups |      |      |      |        |       |       |
| normal vs high | 2.806 | 5.599 | .020 | **15.2** | 1.549 | 149.6 |
| normal vs low | .013  | .017 | .896 | 1.032 | .645  | 1.649 |
| Platelets groups |      |      |      |        |       |       |
| normal vs high | -.884 | 3.817 | .070 | .446 | .186  | 1.003 |
| normal vs low | .477  | 2.397 | .139 | 1.611 | .881  | 2.947 |
| Neutrophil groups |      |      |      |        |       |       |
| normal vs high | .857  | 12.8 | .000 | 2.4   | 1.473 | 3.768 |
| normal vs low | .565  | .594 | .819 | 1.179 | .288  | 4.828 |
| Lymphocytes groups |      |      |      |        |       |       |
| normal vs high | -.200 | .032 | .857 | .806  | .077  | 8.401 |
| normal vs low | .661  | 7.565 | .006 | **1.9** | 1.324 | 3.496 |
| Monocytes groups |      |      |      |        |       |       |
| normal vs high | .775  | 4.406 | .008 | **2.6** | 1.053 | 4.471 |
| normal vs low | 1.459 | 5.890 | .046 | **2.9** | 1.324 | 13.982 |
| Eosinophil groups |      |      |      |        |       |       |
| normal vs high | -1.084 | .641 | .423 | .338 | .024  | 4.805 |
| normal vs low | .184  | .224 | .636 | 1.203 | .561  | 2.579 |
| Age groups |      |      |      |        |       |       |
| <40 y vs >40≤ 65 | .256  | .868 | .346 | 1.292 | .758  | 2.202 |
| <40 y vs > 65 | .722  | 4.816 | .028 | **2.058** | 1.013 | 3.707 |
| Sex ( female Vs male) |      |      |      |        |       |       |
| Obese vs non -obese | .469  | 3.638 | .056 | 1.598 | .987  | 2.588 |
| Hypertension(yes vs no) |      |      |      |        |       |       |
| Diabetes(yes vs no) |      |      |      |        |       |       |
| DM &HTN (yes vs no) |      |      |      |        |       |       |

*Note: Bold values indicate statistical significance.*
Eosinophilia and basophilia were present at admission in 0.8% and 10.8 of patients, respectively. Eosinophils and basophils are phagocytic cells, and this is the cause for their increase. The basophilia present in both survivor and the non-survivor group showed a significant decrease in the follow-up procedure. This decrease indicates recovery in the survivor and decreased immune function in the non-survivor patients. Patients with eosinophilia were not followed up. In this work, both eosinophilia and basophilia do not affect the relative risk of death or prediction of death. Significant eosinopenia was found in non-survivor patients at discharge compared to survivor patients, indicating immune suppression. This is in accordance with previous authors who reported eosinopenia and linked it to poor outcomes [16]. In this work, 4 cases (0.8%) had absolute lymphocytosis. All of them were mild to moderate cases who were recovered with return of the absolute lymphocytes count (ALC) to normal but without significance table 6. The lack of significance is due to the small number of patients. This is the first report about lymphocytosis in COVID-19 patients. The increase in the absolute lymphocyte count may be due to increased CD4 T helper cells that fight infection. In this study, at presentation 6%, 4.6%, 62.2%, and 4% had leukopenia, neutropenia, lymphopenia, and monocytopenia. It is suggested that COVID-19 inhibits hematopoiesis in the bone marrow and promotes apoptosis, leading to decreased cell production with subsequent leukopenia. In addition, the sequestration of different WBC into infected organs or direct infection of WBC by SARS-CoV2 [17-18]. Our work found the highest leukopenia cases in mild to moderate, 37.5%, then severe, 34.4%, then the critical cases, 22.7%. However, the highest neutropenic cases were found in critical cases, 40.9%, then mild to moderate, 36.4%, and severe cases 22.7%. This is in accordance with previous results [19-21]. Both leukopenia and neutropenia did not affect the relative risk of death or the prediction of death in our work. The leukopenic and neutropenic patients in both survivor and the non-survivor group showed an increase in the WBC and neutrophils count. The rise of WBC was significant, while the increase in neutrophils was not significant. The increase in the survivor group was towards the normal values, which indicate recovery. While in the non-survivor, it was above normal values, suggesting the cytokine storm table 6. Physicians must be alert about the cytokine storm and avoid the use of granulocyte colony-stimulating factor for the leukopenia and neutropenia associated with SARS CoV-2 as it may worsen the condition with the early development of acute respiratory distress syndrome. In this study, 62.8% of our patients had lymphopenia at admission, and after one week, it increased to 68.2% (data not shown). This is in accordance with previous authors [18, 22, 23]. Multiple factors are contributing to lymphopenia. It may be due to direct lysis via the virus as lymphocytes have ACE2 receptors on their surface [8]. Or sequestration of the lymphocyte in the lung and gastrointestinal tract, or suppressing hematopoietic stem cells, or the cytokine-mediated disruption of lymphocyte trafficking [24]. The highest proportion of lymphopenia was found in the critical cases 51%, then severe 29.3%, then mild to moderate 19.4%, then the asymptomatic 3%. This agrees with previous authors who reported a correlation between the disease severity and lymphopenia [25-26]. Lymphopenia causes immunosuppression and promotes cytokine storm, which leads to viral persistence, viral replication, multi-organ failure, and eventually death. In this work, the relative risk of death was significantly increased in those with lymphopenia versus the normal group. Also, in bivariate regression analysis, lymphopenia had a 1.9 times risk of death than normal lymphocyte count. So, lymphopenia could be used as a poor prognostic factor and independent predictor for death. In the follow-up of patients with lymphopenia in the non-survivor and survivor patients. There was a significant decrease and a significant increase in the absolute lymphocytes count, respectively. The former indicates more immunosuppression, and the latter indicates recovery. This agrees with previous findings [27]. So, serial assessment of the absolute lymphocyte count is essential. In this study, 4% of our patients had monocytopenia, of which 55% were present in critical cases, 30% in severe, and 15% in mild to moderate. This monocytopenia is consistent with previous results but against their finding that monocytopenia is present in diabetic patients only [28]. In our work, it is present in 35% of diabetics and 65% of non-diabetic. In this work, the relative risk of death was significantly increased in those with monocytopenia versus the normal group. Also, in bivariate regression analysis, monocytopenia had a 2.9 times risk of death than those with normal monocytes count. So, monocytopenia could be used as a poor prognostic factor and an independent predictor of death. The follow-up procedure of patients with monocytopenia showed a significant increase in the survivor patients, which indicates recovery. The non-survivor showed no significant difference, suggesting more impairment in the immune function table 6. The monocytopenia in our work is more aggressive than monocytes as in bivariate regression analysis, the odds ratio of death was 2.9 and 2.2 in those with monocytopenia and monocytes, respectively. This makes us give more attention to those with monocytopenia in COVID-19 patients. In this study, 7.6% and 16.8% of patients had thrombocytosis and thrombocytopenia, respectively. The highest frequency of thrombocytosis and
thrombocytopenia was present in critical cases, then severe, then mild to moderate. The thrombocytosis may occur as a reaction of the bone marrow against viral infection. The thrombocytopenia occurs because of inhibition of hematopoiesis by the virus or secondary hemophagocytic or increased levels of autoantibodies and immune complexes, resulting in the specific destruction of platelets. Pulmonary endothelial cells may activate platelets in the lungs, resulting in aggregation and formation of microthrombi, which increases platelet consumption [29]. The follow-up of the thrombocytosis patients in both survivor and non-survivor showed a significant decrease in the platelet count. On the other hand, the follow-up of the thrombocytopenic patients showed a significant increase in the platelets count in the survivor, indicating recovery and a significant decrease in the non-survivor, which suggests an increase in the severity and complication of the disease [30]. In this work, both thrombocytosis and thrombocytopenia did not affect the relative risk of death. However, the combination of thrombocytopenia with leukocytosis, neutrophilia, and lymphopenia, showed a 2.7 times increase in death than those without, (Table5). So, thrombocytopenia can be used as a marker of poor prognosis in combination with leukocytosis, neutrophilia, and lymphopenia. In this work, in male patients at admission, 71.4%, 1.3%, and 27.2% had normal, high, and low hemoglobin, respectively. In females, 55.3%, 0.6%, and 44% had normal, high, and low hemoglobin at admission. The critical cases in this work showed the highest polycythemia and anemia, 83.3% and 50.9%, respectively. The relative risk of death significantly increased in males with polycythemia versus the normal group. Also, in bivariate regression analysis, polycythemia patients had a 15.2 times risk of death than those with normal hemoglobin. So, polycythemia could be used as a poor prognostic factor and independent predictor for death. The follow-up of patients with polycythemia showed a significant decrease of hemoglobin in the non-survivor patients and the development of anemia, which is associated with the cytokine storm and indicates poor prognosis [31] (Table 6). In this study, the follow-up of anemic patients who survived showed no significant difference in hemoglobin concentration. In contrast, the anemic non-survivor patients showed a significant decrease in hemoglobin, which also is due to the cytokine storm. The follow-up of the normal group of survivor patients showed a significant increase in WBC and its components and the platelet count. The increase in most of the parameters was within the normal values. This denotes the response of the bone marrow and indicates the recovery of patients. In the non-survivor patients, there was a significant increase of WBC and ANC above normal values, a significant decrease of ALC and platelet count. All these changes indicate cytokine storms. The hemoglobin concentration in both survivor and non-survivor patients showed a significant reduction, indicating the occurrence of anemia. The comparison between survivor and non-survivor patients at admission showed significant leukocytosis, neutrophilia, basophilia, increased each of s creatinine, LDH, SGOT, CRP, age, and body mass index at admission in non-survivor when compared to the survivor. This agrees with previous authors [32-33]. At discharge, the comparison between both groups showed persistence of leukocytosis, neutrophilia, high levels of each of s creatinine, LDH, SGOT, CRP, and an increase in the number of days stayed in the hospital. In addition, there was loss of basophilia and acquisition of high SGPT, high ferritin, anemia, thrombocytopenia, lymphopenia, and eosinopenia. The persistence of significant changes in some parameters and new changes in other parameters indicates cytokine storm with an increase in the severity of the disease and an increase in the immune suppression (Table7). In this study, 28.7%, 35%, 19%, 16.8% were hypertensive, diabetic, combined diabetes, and hypertension, and obese. These comorbidities may affect vascular health and lower the ability of the body to tolerate systemic cytokines. At presentation, hypertension, diabetes, age > 40 <65, age >65, combined diabetes and hypertension, and obese patients were statistically significantly related to mortality in the Chi-Square test. However, in the bivariate analysis, they were lost except for diabetes and age >65 y.

Limitation of the study
This study was conducted at one hospital. It may have included disproportionately more patients with poor outcomes. There were no data on post-hospitalization outcomes. Also, some data did not find during collection. There is no measurement of other viruses that cause lymphocytosis in the 4 COVID-19 cases. We could not confirm the cause of leukopenia, neutropenia, lymphopenia, and monocytopenia among the different subjects; either it is due to suppression or sequestration or a combination of both.

Conclusion
Patients with COVID-19 infection may have normal, low, or high values of the different parameters of the complete blood count. The relative risk of death is increased in patients with leukocytosis, neutrophilia, monocytosis, polycythemia, lymphopenia, and monocytopenia. Patients with a combination of leukocytosis, neutrophilia, lymphopenia, and thrombocytopenia have a 2.6 risk of death than others. The independent predictors for death are neutrophilia, monocytosis, lymphopenia, monocytopenia,
The hematological changes in COVID-19 patients; its relations to outcome in a retrospective study in Makkah city

polycythemia, diabetic patients, and age over 65. The follow-up of COVID-19 patients with the complete blood count is recommended to detect early patient changes and early management.

**Conflict of Interest**

None

**Funding**

None

**References**

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382:33-727.
2. WHO. Coronavirus disease (COVID-2019) pandemic. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Accessed 12-4-2021].
3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:13-507.
4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323:9-1061.
5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
6. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;8674(20):34-30229.
7. Tan L, Wang Q, Zhang DY, et al. lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. medRxiv. 2020. doi: https://doi.org/10.1101/2020.03.01.20029074.
8. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis EN, Politou M, Psaltopoulos T, Gerotziafas G, Dimopoulos MA. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95:834–847.
9. WHO. Coronavirus disease (COVID-2019) pandemic. Available from: https://www.worldometers.info/coronavirus/country/saudi-arabia/. [Accessed 12-4-2021]
10. Dennisona D, Al Khaboria M, Al Mamaria S, Aurelioa A, Al Hinaia H, Al Maamare K, Alshekailib J, Al Khadouri G. Circulating activated monocytes the key. GeroScience. 2020;42:1051–1061.
11. Rashidian M. Lymphopenia during the COVID-19 pandemic: an independent predictor and predictive study. medRxiv. 2020. doi: 10.1038/nri.2017.28. Epub 2017 Apr 24
12. Shi S, Liu X, Xiao J, Wang H, Chen L, Li J, Han K. Prediction of adverse clinical outcomes in patients with coronavirus disease 2019. J. Clin. Lab. Anal. 2021;35:1-9.
13. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev. 2020. https://doi.org/10.1093/nsr/nwa041
14. Jakubzick CV, Randolph GJ, Henson PM. Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol. 2017 Jun;17(6):349-362. doi: 10.1038/nri.2017.28. Epub 2017 Apr 24
15. Pence BD. Severe COVID-19 and aging: are monocytes the key. GeroScience. 2020;42:1051–1061.
16. Rodrigo-Muñoz JM, Sastre B, Cañas JA, Gil-Martínez M, Redondo N, del Pozo V. Eosinophil Response Against Classical and Emerging Respiratory Viruses: COVID-19. J Investig Allergol Clin Immunol. 2021;31(2): 94-107
17. Yao XH, Li TY, He ZC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Chin J Pathol. 2020;49:411-417
18. Huang CL, Wang YM, Li XW, Ren LL, Zhao JP, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet. 2020(10223):497–506.
19. Khartabil TA, Russcher H, van der Ven A, de Rijke YB. A summary of the diagnostic and prognostic value of hemocytometry markers in COVID19 patients. Critical Reviews in Clinical Laboratory Sciences. 2020. https://doi.org/10.1080/10408363.2020.1774736
20. López-Pereira P, Iturrate I, de la Cámara R, Cardeñoso L, AlegreA, Aguado B. Can COVID-19 cause severe neutropenia. Clin Case Rep. 2020;8:3348–3350
21. Spencer HC, Wurzburger R. COVID-19 presenting as neutropenic fever. Annals of Hematology. 2020;99(4) https://doi.org/10.1007/s00277-020-04128-w.
22. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of corona virus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720
23. Fan BE, Chong VCL, Chan SSW, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020;95(6):E131- E134.
24. Tavakolpour S, Rakhshandehroo T, Wei E, Rashidian M. Lymphopenia during the COVID-19 infection: What it shows and what can be learned. Immunology Letters. 2020;225:31–32.
25. Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, Zhou W, et al. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-
The hematological changes in COVID-19 patients; its relations to outcome in a retrospective study in Makkah city

19. J Infect. 2020;Aug;81(2):318-356.doi: 10.1016/j.jinf.2020.03.054.

26. Hou H, Zhang B, Huang H, Luo Y, Wu S, Tang G, Liu W, et al. Using IL-2R/lymphocyte for predicting the clinical progression of patients with COVID-19, Clin. Exp. Immunol. 2020;201(1):76-84.doi: 10.1111/cei.13450.

27. Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5:33.

28. Alzaid F, Julla JB, Diedisheim M, Potier C, Potier L, Velho G, Gaborit B, et al. Monocytopenia, monocyte morphological anomalies and hyperinflammation characterize severe COVID-19 in type 2 diabetes. EMBO Molecular Medicine. 2020;12: e13038.

29. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020; 99:1205–1208.

30. Zhu Y, Zhang J, Li Y, Liu F, Zhou Q, Peng Z. Association between thrombocytopenia and 180-day prognosis of COVID-19 patients in intensive care units: A two-center observational study. Plos one. 2021;16(3):1-15; e0248671.

31. Castelli V, Cimini A, Ferri C. Cytokine Storm in COVID-19: “When You Come Out of the Storm, You Won’t Be the Same Person Who Walked in” .Front. Immunol. 2020;11:2132. doi: 10.3389/fimmu.2020.02132.

32. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.

33. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan. JAMA. 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585.